Background/Aims: The diagnostic accuracy of the Cuban version of the revised Addenbrooke’s Cognitive Examination (ACE-R) in identifying mild cognitive impairment (MCI) in comparison with the Mini-Mental State Examination (MMSE) was assessed. Methods: The Cuban ACE-R was administered to a group of 129 elderly subjects (92 cognitively healthy and 37 subjects with MCI). The t tests for independent samples were used to compare scores of different psychometric scales between groups, and effect sizes (Cohen’s d) were calculated. Cronbach’s coefficient α was used to evaluate the reliability of psychometric scales. The validity of ACE-R to screen for MCI was assessed by receiver operating characteristic (ROC) curves. Results: The Cuban ACE-R had reliable internal consistency (Cronbach’s coefficient α = 0. 879). The optimal cut-off score for ACE-R for detecting MCI was 84/85. The sensitivity and specificity of ACE-R to screen for MCI was superior to those of MMSE. The area under the ROC curve of the Cuban ACE-R was much larger than that of MMSE (0.93 and 0.63) for detecting MCI. Conclusion: The Cuban ACE-R is a valid screening tool for detecting cognitive impairment. It is more sensitive and accurate in screening for MCI than MMSE.

Keywords:
Addenbrooke’s Cognitive Examination-Revised, Mild cognitive impairment, Mini-Mental State Examination, Elderly, Cuban population
1.
Alzheimer’s Disease International/Bupa: La demencia en América: el coste y la prevalencia del Alzheimer y otros tipos de demencia. Bupa, Octubre 2013.
2.
Bosch-Bayard RI, Llibre-Rodríguez JJ, Fernández-Seco A, Borrego-Calzadilla C, Carrasco-García MR, Zayas-Llerena T, et al: Cuba’s strategy for Alzheimer disease and dementia syndromes. MEDICC Rev 2016; 18: 9–13.
3.
WHO: The Epidemiology and Impact of Dementia: Current State and Future Trends 2015. http://www.who.int/mental_health/neurology/dementia/en/.
4.
Carnero-Pardo C: Es hora de jubilar al Mini-Mental? Neurologia 2014; 29: 473–481.
5.
Lorentz WJ, Scanlan JM, Borson S: Brief screening tests for dementia. Can J Psychiatry 2002; 47: 723–733.
6.
Folstein MF, Folstein SE, McHugh PR: Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–198.
7.
Simard M: The Mini-Mental State Examination: strengths and weaknesses of a clinical instrument. Can Alzheimer Dis Rev 1998; 10–12.
8.
Scazufca M, Almeida OP, Vallada HP, Tasse WA, Menezes PR: Limitations of the Mini-Mental State Examination for screening dementia in a community with low socioeconomic status: results from the Sao Paulo Ageing & Health Study. Eur Arch Psychiatry Clin Neurosci 2009; 259: 8–15.
9.
Wind AW, Schelleveis FG, Van Staversen G, Scholten RJ, Jonker C, Van Eijk J: Limitations of the Mini-Mental State Examination in diagnosing dementia in general practice. Int J Geriatr Psychiatry 1997; 12: 101–108.
10.
Broche-Pérez Y: Alternativas instrumentales para la exploración cognitiva breve del adulto mayor: Más allá del Minimental Test. Rev Cubana Med Gen 2017; 36.
11.
Ismail Z, Rajji TK, Shulman KI: Brief cognitive screening instruments: an update. Int J Geriatr Psychiatry 2010; 25: 111–120.
12.
Mitchell AJ: A meta-analysis of the accuracy of the Mini-Mental State Examination in the detection of dementia and mild cognitive impairment. J Psychiatr Res 2009; 43: 411–431.
13.
Fang R, Wang G, Huang Y, Zhuang JP, Tang HD, Wang Y, et al: Validation of the Chinese version of Addenbrooke’s Cognitive Examination-Revised for screening mild Alzheimer’s disease and mild cognitive impairment. Dement Geriatr Cogn Disord 2014; 37: 223–231.
14.
Yoshida H, Terada S, Honda H, Kishimoto Y, Takeda N, Oshima E, et al: Validation of the revised Addenbrooke’s Cognitive Examination (ACE-R) for detecting mild cognitive impairment and dementia in a Japanese population. Int Psychogeriatr 2012; 24: 28–37.
15.
Muñoz-Neira C, Henríquez F, Ihnen J, Sánchez M, Flores P, Slachevsky A: Propiedades psicométricas y utilidad diagnóstica del Addenbrooke’s Cognitive Examination-Revised (ACE-R) en una muestra de ancianos chilenos. Rev Med Chile 2012; 140: 1006–1013.
16.
Reyes MA, Lloret SP, Gerscovich ER, Martin ME, Leiguarda R, Merello M: Addenbrooke´s Cognitive Examination validation in Parkinson’s disease. Eur J Neurol 2009; 16: 142–147.
17.
Chade A, Roca M, Torralva T, Gleichgerrcht E, Fabbro N, Gómez-Arévalo G, et al: Detecting cognitive impairment in patients with Parkinson’s disease using a brief cognitive screening tool: Addenbrooke´s Cognitive Examination (ACE). Dement Neuropsychol 2008; 2: 197–200.
18.
Alexopoulos P, Ebert A, Richter-Schmidinger T, Schöll E, Natale B, Aguilar CA, et al: Validation of the German revised Addenbrooke’s cognitive examination for detecting mild cognitive impairment, mild dementia in Alzheimer’s disease and frontotemporal lobar degeneration. Dement Geriatr Cogn Disord 2010; 29(suppl 5):448–456.
19.
Mioshi E, Dawson K, Mitchell J, Arnold R, Hodges JR: The Addenbrooke’s Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry 2006; 21: 1078–1085.
20.
Torralva T, Roca M, Gleichgerrcht E, Bonifacio A, Raimond C, Manes F: Validación de la versión en español del Addenbrooke’s Cognitive Examination-Revisado (ACE-R). Neurologia 2011; 26: 351–356.
21.
Rittman T, Ghosh B, McColgan P, Breen DP, Evans J, Williams-Gray C, et al: The Addenbrooke’s Cognitive Examination for the differential diagnosis and longitudinal assessment of patients with parkinsonian disorders. J Neurol Neurosurg Psychiatry 2013; 84: 544–551.
22.
Roca M, Torralva T, López P, Marengo J, Cetkovich M, Manes F: Diferenciación entre demencias en estadio inicial y depresión utilizando la versión española del Addenbrooke’s Cognitive Examination. Rev Neurol 2008; 46: 340–343.
23.
Mathew R, Bak TH, Hodges JR: Screening for cognitive dysfunction in corticobasal syndrome: utility of Addenbrooke’s cognitive examination. Dement Geriatr Cogn Disord 2011; 31: 254–258.
24.
Carvalho VA, Caramelli P: Brazilian adaptation of the Addenbrooke’s Cognitive Examination-Revised (ACE-R). Dement Neuropsychol 2007; 2: 212–216.
25.
Konstantinopoulou E, Kosmidis MH, Ioannidis P, Kiosseoglou G, Karacostas D, Taskos N: Adaptation of Addenbrooke’s Cognitive Examination-Revised for the Greek population. Eur J Neurol 2011; 18: 442–447.
26.
Kwak YT, Yang Y, Kim GW: Korean Addenbrooke’s Cognitive Examination Revised (K-ACER) for differential diagnosis of Alzheimer’s disease and subcortical ischemic vascular dementia. Geriatr Gerontol Int 2010; 10(suppl 4):295–301.
27.
Ospina NA: Adaptación y Validación en Colombia del Addenbrooke’s Cognitive Examination-Revisado (ACE-R) en pacientes con Deterioro Cognoscitivo Leve y Demencia. Bogotá, Universidad Nacional de Colombia, 2015.
28.
Roberts RO, Geda YE, Knopman DS: The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology 2008; 30: 58–69.
29.
Petersen RC: Mild cognitive impairment: transition between aging and Alzheimer’s disease. Neurologia 2000; 15: 93–101.
30.
Yesavage JA: Geriatric Depression Scale. Psychopharmacol Bull 1988; 24: 709–11.
31.
Zung WWK: A rating instrument for anxiety disorders. Psychosomatics 1971; 12: 371–379.
32.
Cohen J: Statistical Power Analysis for the Behavioral Sciences, ed 2. New York, Academic Press, 1988.
33.
Swets JA: Measuring the accuracy of diagnostic system. Science 1998; 240: 1258–93.
34.
Pigliautile M, Ricci M, Mioshi E, Ercolani S, Mangialasche F, Monastero R, et al: Validation study of the Italian Addenbrooke’s Cognitive Examination Revised in a young-old and old-old population. Dement Geriatr Cogn Disord 2011; 32: 301–307.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.